Enzon Pharmaceuticals Inc
OTC:ENZN
Enzon Pharmaceuticals Inc
OTC:ENZN
Price:
6
USD
8.11%
Market Cap:
$4.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Enzon Pharmaceuticals Inc
OTC:ENZN
|
US |
|
THG PLC
LSE:THG
|
UK |
|
HMS Networks AB
STO:HMS
|
SE |
|
S
|
Sunwels Co Ltd
TSE:9229
|
JP |
|
M
|
Meshek Energy-Renewable Energies Ltd
TASE:MSKE
|
IL |
|
Tigers Polymer Corp
TSE:4231
|
JP |
|
AAC Technologies Holdings Inc
HKEX:2018
|
CN |
|
G
|
Greatland Resources Ltd
SWB:U0Y
|
AU |
|
Genscript Biotech Corp
HKEX:1548
|
CN |
|
Bloomsbury Publishing PLC
LSE:BMY
|
UK |
|
Panca Anugrah Wisesa Tbk PT
IDX:MGLV
|
ID |
|
Aiful Corp
TSE:8515
|
JP |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd
SSE:600663
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
ENZN
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 6 USD,
Enzon Pharmaceuticals Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENZN Multiples-Based Value
LOCKED
Multiples Across Competitors
ENZN Competitors Multiples
Enzon Pharmaceuticals Inc Competitors
Enzon Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Enzon Pharmaceuticals Inc
OTC:ENZN
|
4.5m USD | 0 | -80.5 | 7.2 | 7.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.2 | 90 | 14.9 | 20.7 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 109.7 | -1 712.3 | 15 906.4 | -1 796.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.8 | 19.9 | 12.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.4 | 28.5 | 21.4 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
